{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=45", "query": { "condition": "Relapsed/Refractory ALL", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 3665, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T12:51:41.118Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03873493", "title": "A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "T-cell Prolymphocytic Leukemia (T-PLL)", "Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-01-14", "completion_date": "2021-11-04", "has_results": true, "last_update_posted_date": "2022-12-19", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03873493" }, { "nct_id": "NCT05027867", "title": "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer", "Small Cell Lung Carcinoma", "Small Cell Lung Cancer Extensive Stage", "Small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-12-06", "completion_date": "2022-08-26", "has_results": false, "last_update_posted_date": "2023-08-16", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 9, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027867" }, { "nct_id": "NCT01799889", "title": "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Diffuse Large B-cell Lymphoma", "Non-FL Indolent Non-Hodgkin's Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Entospletinib MM", "type": "DRUG" }, { "name": "Entospletinib SDD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2013-03-14", "completion_date": "2020-01-30", "has_results": true, "last_update_posted_date": "2020-11-19", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01799889" }, { "nct_id": "NCT02477891", "title": "Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2019-01-15", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Gilroy", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477891" }, { "nct_id": "NCT03223610", "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Revlimid (lenalidomide)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 155, "start_date": "2018-02-09", "completion_date": "2029-12-12", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03223610" }, { "nct_id": "NCT05455320", "title": "A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 864, "start_date": "2022-10-13", "completion_date": "2028-05-25", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 40, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05455320" }, { "nct_id": "NCT00002588", "title": "Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1994-08", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002588" }, { "nct_id": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Recurrent Myelodysplastic Syndrome", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "Navitoclax", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-01-12", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564650" }, { "nct_id": "NCT05698888", "title": "Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, Adult", "Multiple Myeloma", "Lymphoma" ], "interventions": [ { "name": "VP301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virtuoso BINco, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-11-29", "completion_date": "2023-06-19", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05698888" }, { "nct_id": "NCT00003340", "title": "Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-11", "completion_date": "2000-02", "has_results": false, "last_update_posted_date": "2014-05-02", "last_synced_at": "2026-11-13T12:51:41.118Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003340" } ] }